Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (251)	3/17/2000 12:51:00 PM
From: thebeach	Respond to of 356

PROCYON BIOPHARMA INC ("PBP-V") - CEO Emphasizes: Company not Linked to Human Genome Project The President and CEO of Procyon BioPharma Inc.("Procyon") emphasized that the activities of Procyon are not linked to the Human Genome Project and that shareholders need not be concerned about the impact of the Clinton, Blair announcement in this regard. Mr. Mader pointed out that Procyon is on target with the development of its two core technologies and its two near-term products. "Since moving our head office to Montreal, Procyon has benefitted from the synergies of the vibrant biotech environment in this region," he said. "We announced an agreement by which Biovail has acquired the Canadian rights to FIBROSTAT(TM), our topical cream in late Phase II development for the treatment of scars resulting from surgery or burns." The agreement provides Procyon with up-front financing to complete development of the product and a milestone payment upon product approval, in addition to double-digit royalties on sales. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the CDNX under the ticker symbol, PBP. TEL: (514) 685-9283 Hans J. Mader, President and CEO Procyon BioPharma Inc. E-mail: hmader@procyonbiopharma.com Web site: www.procyonbiopharma.com TEL: (514) 843-2309 Nathalie Bourque NATIONAL Public Relations ______________________________